Differences in Alzheimer's disease blood biomarker stability: Implications for the use of tau/amyloid ratios
Open Access
- 1 April 2025
- journal article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (4) , e70173
Abstract
INTRODUCTION: We compare the stability of phosphorylated tau (p‐tau)217, amyloid beta (Aβ)42, Aβ40, Aβ42/40, and p‐tau217/Aβ42 at different storage temperatures.METHODS: Ten ethylenediaminetetraacetic acid–plasma sample aliquots stored at frozen, refrigerated, and ambient temperatures were tested at various timepoints up to 30 days. The mean percent change from baseline was calculated.RESULTS: Aβ42 and Aβ40 concentrations decreased by >15% after 6 hours at ambient temperature and after 24 hours refrigerated, while p‐tau217 remained stable over 72 hours with < 10% deviation from baseline at either storage temperature. The Aβ42/40 ratio remained relatively constant as each analyte concentration decreased concurrently, while the p‐tau217/Aβ42 ratio deviated from baseline over time. All biomarkers were stable up to 30 days frozen.DISCUSSION: Differences in the stability of Aβ42 and p‐tau217 may lead to altered p‐tau217/Aβ42 ratio results if samples are not handled properly during the pre‐analytical testing phase. Ideally, samples should be frozen promptly and sent to the laboratory frozen.Highlights: Plasma phosphorylated tau (p‐tau)217, amyloid beta (Aβ)42, Aβ40, Aβ42/40, and p‐tau217/Aβ42 stability was assessed. P‐tau217 was stable, but Aβ42 and Aβ40 started decreasing by 6 hours at ambient temperature. The analyte stability differences led to falsely increased p‐tau217/Aβ42 ratios. Increases > 15% were seen in p‐tau217/Aβ42 after 6 hours at ambient temperature or 24 hours at 4°C.Keywords
This publication has 22 references indexed in Scilit:
- Effects of certain pre-analytical factors on the performance of plasma phospho-tau217Alzheimer's Research & Therapy, 2024
- Pre-Analytical Variables Influencing Stability of Blood-Based Biomarkers of NeuropathologyJournal of Alzheimer’s Disease, 2023
- A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain casesNature Aging, 2023
- Prevalence of Alzheimer's disease dementia in the 50 US states and 3142 counties: A population estimate using the 2020 bridged‐race postcensal from the National Center for Health StatisticsAlzheimer's & Dementia, 2023
- Preanalytical stability of plasma biomarkers for Alzheimer's disease pathologyAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023
- Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applicationsMolecular Neurodegeneration, 2023
- Impact of pre‐analytical sample handling factors on plasma biomarkers of Alzheimer's diseaseJournal of Neurochemistry, 2023
- Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s diseaseBrain, 2022
- NIA‐AA Research Framework: Toward a biological definition of Alzheimer's diseaseAlzheimer's & Dementia, 2018
- Guidelines for the standardization of preanalytic variables for blood‐based biomarker studies in Alzheimer's disease researchAlzheimer's & Dementia, 2014